June 4 2024 is an important date for MDMA-Assisted Therapy

The FDA is currently in the final stages of the MDMA-Assisted Therapy approval process, with the decision expected in August 2024. The next stage in the approval process is the meeting of the FDA Advisory Committee on June 4 to review Lykos Therapeutics’ application.

MAPS PBC No Longer a Public Benefit Corporation

The Multidisciplinary Association for Psychedelic Studies (MAPS) has been admirably resistant to the pressures of the market economy for a long time. But the capital have won, again, and in a somewhat sad move, MAPS’s pharmaceutical arm, the MAPS Public Benefit Corporation, has now become a conventionally structured pharmacological company called Lykos Pharmaceutical.